Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of ...
Lecanemab's maintenance dosing regimen is now approved for early-stage Alzheimer's, transitioning from biweekly to once every four weeks after 18 months. Phase 2 and 3 trials confirmed lecanemab's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results